Jump to: navigation, search
Therapeutic monoclonal antibody
Source Human
Target CTLA-4
CAS number 477202-00-9
ATC code  ?
PubChem  ?
Chemical data
Formula C6742H9972N1732O2004S40 
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

WikiDoc Resources for



Most recent articles on Ipilimumab

Most cited articles on Ipilimumab

Review articles on Ipilimumab

Articles on Ipilimumab in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ipilimumab

Images of Ipilimumab

Photos of Ipilimumab

Podcasts & MP3s on Ipilimumab

Videos on Ipilimumab

Evidence Based Medicine

Cochrane Collaboration on Ipilimumab

Bandolier on Ipilimumab

TRIP on Ipilimumab

Clinical Trials

Ongoing Trials on Ipilimumab at Clinical Trials.gov

Trial results on Ipilimumab

Clinical Trials on Ipilimumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ipilimumab

NICE Guidance on Ipilimumab


FDA on Ipilimumab

CDC on Ipilimumab


Books on Ipilimumab


Ipilimumab in the news

Be alerted to news on Ipilimumab

News trends on Ipilimumab


Blogs on Ipilimumab


Definitions of Ipilimumab

Patient Resources / Community

Patient resources on Ipilimumab

Discussion groups on Ipilimumab

Patient Handouts on Ipilimumab

Directions to Hospitals Treating Ipilimumab

Risk calculators and risk factors for Ipilimumab

Healthcare Provider Resources

Symptoms of Ipilimumab

Causes & Risk Factors for Ipilimumab

Diagnostic studies for Ipilimumab

Treatment of Ipilimumab

Continuing Medical Education (CME)

CME Programs on Ipilimumab


Ipilimumab en Espanol

Ipilimumab en Francais


Ipilimumab in the Marketplace

Patents on Ipilimumab

Experimental / Informatics

List of terms related to Ipilimumab


Ipilimumab (also known as MDX-010) is a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex. It is intended to be used as a drug to activate the immune system. Ipilimumab is undergoing clinical trials for the treatment of melanoma.[1]

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is believed to play a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

As of October 2007 there are two fully human anti CTLA-4 [1] monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 isotype, and Tremelimumab (from Pfizer) which is an IgG2 isotype.


  1. ClinicalTrials.gov NCT00094653